{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:18:59Z","timestamp":1790313539034,"version":"4.1.0"},"reference-count":23,"publisher":"S. Karger AG","issue":"8","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Nephrol"],"published-print":{"date-parts":[[2020]]},"abstract":"<b><i>Background:<\/i><\/b> Patients with end-stage renal disease (ESRD) undergoing chronic hemodialysis are at high mortality and cardiovascular risk. This study was aimed to assess whether the CHA<sub>2<\/sub>DS<sub>2<\/sub>-VASc score may be used for risk stratification of this population. <b><i>Methods:<\/i><\/b> Included were patients undergoing chronic hemodialysis at Meir Medical Center. The CHA<sub>2<\/sub>DS<sub>2<\/sub>-VASc score was calculated for each patient at the initiation of hemodialysis. Patients were classified into 3 groups according to the CHA<sub>2<\/sub>DS<sub>2<\/sub>-VASc score: 0\u20133 (low), 4\u20135 (intermediate), and \u22656 (high). The primary endpoint was the composite of all-cause mortality, myocardial infarction, and stroke during the first year of hemodialysis. <b><i>Results:<\/i><\/b> Of the 457 patients with ESRD, 181 (40%) had low, 193 (42%) intermediate, and 83 (18%) high CHA<sub>2<\/sub>DS<sub>2<\/sub>-VASc scores. During the first year of hemodialysis, 109 (23.8%) patients died, 17 (3.7%) had a stroke, and 28 (6.1%) had a myocardial infarction. Compared to patients in the low CHA<sub>2<\/sub>DS<sub>2<\/sub>-VASc score group, those in the intermediate and high score groups had higher risk for the composite endpoint (OR: 2.6, 95% CI: 1.6\u20134.2, <i>p<\/i> &#x3c; 0.01 and OR: 4.2, 95% CI: 2.3\u20137.5, <i>p<\/i> &#x3c; 0.01, respectively). Each 1-point increase in CHA<sub>2<\/sub>DS<sub>2<\/sub>-VASc score was associated with a 38% increased risk for the composite endpoint, a 19% increased risk for 1-year myocardial infarction, and a 29% increased risk for 1-year stroke. <b><i>Conclusions:<\/i><\/b> Patients with ESRD are at an extremely high mortality and cardiovascular risk within the first year of hemodialysis. The CHA<sub>2<\/sub>DS<sub>2<\/sub>-VASc score was strongly associated with adverse outcomes and may be used for risk stratification of these patients. <\/jats:p>","DOI":"10.1159\/000508836","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T21:00:32Z","timestamp":1595451632000},"page":"635-640","source":"Crossref","is-referenced-by-count":18,"title":["Assessment of the CHA<sub>2<\/sub>DS<sub>2<\/sub>-VASc Score in Predicting Mortality and Adverse Cardiovascular Outcomes of Patients on Hemodialysis"],"prefix":"10.1159","volume":"51","author":[{"given":"Miri","family":"Schamroth Pravda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1894-6956","authenticated-orcid":false,"given":"Keren","family":"Cohen Hagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Topaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0989-187X","authenticated-orcid":false,"given":"Nili","family":"Schamroth Pravda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeen","family":"Makhoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mony","family":"Shuvy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Benchetrit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abid","family":"Assali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pereg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2020,7,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60572-8"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.19.2560"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041031"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025920"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.1998.v32.pm9820470"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00657.x"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfz023"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1160\/TH16-11-0876"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.22.2864"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2016.02.010"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2017.10.012"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-0435"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezw313"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2000.00173.x"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2002.00600.x"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/17.3.435"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.118.034588"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.6102"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1159\/000455239"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2017.01.053"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnesp.2019.10.019"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2016.04.151"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03860609"}],"container-title":["American Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/508836","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/508836","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:14:47Z","timestamp":1745424887000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000508836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":23,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8,19]]},"published-print":{"date-parts":[[2020,8,25]]}},"URL":"https:\/\/doi.org\/10.1159\/000508836","archive":["Portico"],"relation":{},"ISSN":["0250-8095","1421-9670"],"issn-type":[{"value":"0250-8095","type":"print"},{"value":"1421-9670","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]}}}